From past interactions we've seen with the FDA, "p
Post# of 148168
(Total Views: 456)
Posted On: 02/23/2021 11:20:05 AM
Re: generactor #79466
From past interactions we've seen with the FDA, "path forward" most likely means further review with accompanying delays of some sort or another. It would be a total shock for the FDA to mirror even a small percentage of the optimism on this board. That's not to say that optimism isn't warranted (or unwarranted for that matter).
All Nader did was tell us that the results have been unblinded. Beyond that we have no clue as to how those results are being perceived. If we have to wait more than 2-3 weeks for any definitive ruling, Nader will probably issue another PR stating that Cytodyn is awaiting further guidance from the FDA and {how much he appreciates their input}. What else can he do? What else can we do, but wait.
All Nader did was tell us that the results have been unblinded. Beyond that we have no clue as to how those results are being perceived. If we have to wait more than 2-3 weeks for any definitive ruling, Nader will probably issue another PR stating that Cytodyn is awaiting further guidance from the FDA and {how much he appreciates their input}. What else can he do? What else can we do, but wait.
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼